Dongsung Pharm (KO:002210) — Market Cap & Net Worth
Market Cap & Net Worth: Dongsung Pharm (002210)
Dongsung Pharm (KO:002210) has a market capitalization of $22.30 Million (₩32.90 Billion) as of September 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #24850 globally and #1794 in its home market, demonstrating a -7.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dongsung Pharm's stock price ₩1348.00 by its total outstanding shares 24408359 (24.41 Million). Also see Dongsung Pharm total assets for a full breakdown of the balance sheet.
Dongsung Pharm Market Cap History: 2015 to 2026
Dongsung Pharm's market capitalization history from 2015 to 2026. Data shows change from $81.71 Million to $22.30 Million (-11.41% CAGR). Also see 002210 cash flow metrics for how efficiently the company converts equity into cash flow.
Dongsung Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dongsung Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 002210 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Dongsung Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $69.31 Million | $79.72 Billion | -$1.66 Billion | 0.00x | N/A |
| 2017 | $81.88 Million | $82.39 Billion | -$198.26 Million | 0.00x | N/A |
| 2018 | $247.29 Million | $91.91 Billion | -$5.74 Billion | 0.00x | N/A |
| 2019 | $265.49 Million | $86.54 Billion | -$8.39 Billion | 0.00x | N/A |
| 2020 | $205.94 Million | $87.80 Billion | -$14.08 Billion | 0.00x | N/A |
| 2021 | $138.62 Million | $84.41 Billion | -$4.31 Billion | 0.00x | N/A |
| 2022 | $110.50 Million | $93.33 Billion | -$2.12 Billion | 0.00x | N/A |
| 2023 | $95.28 Million | $88.59 Billion | -$2.07 Billion | 0.00x | N/A |
| 2024 | $76.59 Million | $88.45 Billion | -$7.25 Billion | 0.00x | N/A |
Competitor Companies of 002210 by Market Capitalization
Companies near Dongsung Pharm in the global market cap rankings as of September 18, 2026. Review 002210 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Dongsung Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Dongsung Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Dongsung Pharm's market cap moved from $81.71 Million to $ 22.30 Million, with a yearly change of -11.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩22.30 Million | +38.54% |
| 2025 | ₩16.09 Million | -78.98% |
| 2024 | ₩76.59 Million | -19.62% |
| 2023 | ₩95.28 Million | -13.77% |
| 2022 | ₩110.50 Million | -20.29% |
| 2021 | ₩138.62 Million | -32.69% |
| 2020 | ₩205.94 Million | -22.43% |
| 2019 | ₩265.49 Million | +7.36% |
| 2018 | ₩247.29 Million | +202.02% |
| 2017 | ₩81.88 Million | +18.14% |
| 2016 | ₩69.31 Million | -15.18% |
| 2015 | ₩81.71 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Dongsung Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.30 Million USD |
| MoneyControl | $22.30 Million USD |
| MarketWatch | $22.30 Million USD |
| marketcap.company | $22.30 Million USD |
| Reuters | $22.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dongsung Pharm
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-… Read more